GLUE Quote, Financials, Valuation and Earnings

MEI Pharma has a net margin of -258.89% compared to Monte Rosa Therapeutics's net margin of --. Monte Rosa Therapeutics's return on equity of -- beat MEI Pharma's return on equity of --.

Monte Rosa Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 126.63%. On the other hand MEI Pharma has an analysts' consensus of -- which suggests that it could grow by 719.67%. Given that MEI Pharma has higher upside potential than Monte Rosa Therapeutics, analysts believe MEI Pharma is more attractive than Monte Rosa Therapeutics.

Monte Rosa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MEI Pharma has a beta of 0.790, suggesting its less volatile than the S&P 500 by 21.017%.

Monte Rosa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MEI Pharma offers a yield of 0% to investors and pays a quarterly dividend of $1.75 per share. Monte Rosa Therapeutics pays -- of its earnings as a dividend. MEI Pharma pays out 65.59% of its earnings as a dividend. MEI Pharma's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Monte Rosa Therapeutics quarterly revenues are $9.2M, which are larger than MEI Pharma quarterly revenues of --. Monte Rosa Therapeutics's net income of -$23.9M is lower than MEI Pharma's net income of -$8M. Notably, Monte Rosa Therapeutics's price-to-earnings ratio is -- while MEI Pharma's PE ratio is 1.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics is -- versus 0.15x for MEI Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -258.89% compared to Monte Rosa Therapeutics's net margin of 24.21%. Monte Rosa Therapeutics's return on equity of -- beat Novartis AG's return on equity of 41.89%.

Monte Rosa Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 126.63%. On the other hand Novartis AG has an analysts' consensus of -- which suggests that it could grow by 15.9%. Given that Monte Rosa Therapeutics has higher upside potential than Novartis AG, analysts believe Monte Rosa Therapeutics is more attractive than Novartis AG.

Monte Rosa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.557, suggesting its less volatile than the S&P 500 by 44.326%.

Monte Rosa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.8% to investors and pays a quarterly dividend of $3.74 per share. Monte Rosa Therapeutics pays -- of its earnings as a dividend. Novartis AG pays out 48.86% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Monte Rosa Therapeutics quarterly revenues are $9.2M, which are smaller than Novartis AG quarterly revenues of $13.2B. Monte Rosa Therapeutics's net income of -$23.9M is lower than Novartis AG's net income of $3.2B. Notably, Monte Rosa Therapeutics's price-to-earnings ratio is -- while Novartis AG's PE ratio is 11.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics is -- versus 4.04x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -258.89% compared to Monte Rosa Therapeutics's net margin of -63.65%. Monte Rosa Therapeutics's return on equity of -- beat Revance Therapeutics's return on equity of --.

Monte Rosa Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 126.63%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 149.58%. Given that Revance Therapeutics has higher upside potential than Monte Rosa Therapeutics, analysts believe Revance Therapeutics is more attractive than Monte Rosa Therapeutics.

Monte Rosa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

Monte Rosa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Monte Rosa Therapeutics quarterly revenues are $9.2M, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Monte Rosa Therapeutics's net income of -$23.9M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Monte Rosa Therapeutics's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics is -- versus 1.15x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vera Therapeutics has a net margin of -258.89% compared to Monte Rosa Therapeutics's net margin of --. Monte Rosa Therapeutics's return on equity of -- beat Vera Therapeutics's return on equity of --.

Monte Rosa Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 126.63%. On the other hand Vera Therapeutics has an analysts' consensus of -- which suggests that it could grow by 55.96%. Given that Monte Rosa Therapeutics has higher upside potential than Vera Therapeutics, analysts believe Monte Rosa Therapeutics is more attractive than Vera Therapeutics.

Monte Rosa Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vera Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Monte Rosa Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vera Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics pays -- of its earnings as a dividend. Vera Therapeutics pays out -- of its earnings as a dividend.

Monte Rosa Therapeutics quarterly revenues are $9.2M, which are larger than Vera Therapeutics quarterly revenues of --. Monte Rosa Therapeutics's net income of -$23.9M is higher than Vera Therapeutics's net income of -$46.6M. Notably, Monte Rosa Therapeutics's price-to-earnings ratio is -- while Vera Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics is -- versus -- for Vera Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.